Science Implementation Spółka z Ograniczoną Odpowiedzialnością Spółka Komandytowa (KRS 0000860129, NIP 9571126710) is a Polish company, headquartered in Gdańsk, Pomorskie voivodeship. Science Implementation Spółka z Ograniczoną Odpowiedzialnością operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since September 15, 2020. Science Implementation Spółka z Ograniczoną Odpowiedzialnością's most recently reported net revenue was 0 PLN for 2024.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Science Implementation
Identity
- Name
- Science Implementation Spółka z Ograniczoną Odpowiedzialnością Spółka Komandytowa
- Legal form
- Limited Partnership (Sp.k.)
- Founded
- September 15, 2020
- Registry status as of
- December 3, 2025
- Latest entry
- October 3, 2025
- Founding act
- UMOWA SPÓŁKI KOMANDYTOWEJ Z DNIA 28 SIERPNIA 2020R., ŁUKASZ GANCZEWSKI - NOTARIUSZ, KAROLINA ADAM, JOANNA TUMASZ NOTARIU…
Articles of association history (1)
- UMOWA SPÓŁKI KOMANDYTOWEJ Z DNIA 28 SIERPNIA 2020R., ŁUKASZ GANCZEWSKI - NOTARIUSZ, KAROLINA ADAM, JOANNA TUMASZ NOTARIUSZE SPÓŁKA PARTNERSKA, REPERTORIUM A NR 4487/2020
Activities
Other activities
Address and contact
- Address
- UL. BUDOWLANYCH, 65, 80-298, GDAŃSK, POLSKA
- Voivodeship
- POMORSKIE
- District
- GDAŃSK
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-18747-92049-TFWBW-08
- Coordinates
- 54.3598, 18.6360approx.
Risk and payment profile - Science Implementation
Credibility rating
35.6 / 100
Poor credibility
Insolvency risk
High
Significant formal threat
Closure risk
39
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/6 yrs
Board changes
0
0/6 yrs
PKD changes
0
0/6 yrs
Name changes
0
0/6 yrs
Data from 6 years of registry activity.
Credibility history
Payment reliability score from 2021–2024
Current: E (36/100)
Trend: improving (+5.7 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2021–2024
Current: 1.0 K PLN
Safe: 142.25 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Science Implementation
Founded
September 15, 2020
5 years in operation
Legal form
Limited Partnership (Sp.k.)
Registry: RejP
Headquarters
GDAŃSK
POMORSKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Shareholders
3
shareholders
Filed years
4 years
2021–2024
Registry entries
14
latest: October 3, 2025
Revenue
0 PLN
2024
Net profit
8.1 K PLN
2024
Assets
271.3 K PLN
2024
Equity
22.2 K PLN
2024
EBITDA
-840 PLN
2024
Valuation
40.2 K PLN
Low confidence
Low confidence
Directories and rankings for this location
Public procurement
Trademarks
Reviews
Rate business credibility - Science Implementation.
No ratings
Related articles
Explainer
Mabion in 2026: Polish monoclonal-antibody maker, mWIG40 issuer from Konstantynów Łódzki, Novavax COVID-19 antigen contract
Mabion S.A. (KRS 0000340462), headquartered at ul. Gen. Mariana Langiewicza 60 in Konstantynów Łódzki, is a Polish biotech specialising in monoclonal-antibody production (key project: MabionCD20, a rituximab biosimilar) and in CDMO (Contract Development and Manufacturing Organization) work. Its main international contract is manufacturing the COVID-19 vaccine antigen for Novavax. Founded in 2007 by Maciej Wieczorek and listed on the WSE since 2010, the company is an mWIG40 constituent, with a three-member management board and a five-member supervisory board.
Explainer
Ryvu Therapeutics in 2026: a Kraków oncology biotech, RVU120 in Phase II clinical trials, a six-member management board, an mWIG40 issuer after the Selvita spin-off
Ryvu Therapeutics S.A. (KRS 0000367359), headquartered at ul. Leona Henryka Sternbacha 2 in Kraków, is a Polish oncology biotech developing anti-cancer small-molecule drugs. It has operated as a stand-alone company since the 2019 spin-off from Selvita (which retained the R&D-services business). Flagship project: RVU120 – a CDK8/19 kinase inhibitor in Phase II trials across multiple oncological indications. Listed on the WSE since 2019 and an mWIG40 constituent, with a six-member management board and a seven-member supervisory board.